Cite
Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
MLA
Wang, Zexing, et al. “Risk of Gastrointestinal Perforation in Cancer Patients Receiving Ramucirumab: A Meta-Analysis of Randomized Controlled Trials.” Journal of Chemotherapy (Taylor & Francis Ltd), vol. 28, no. 4, Aug. 2016, pp. 328–34. EBSCOhost, https://doi.org/10.1179/1973947815Y.0000000053.
APA
Wang, Z., Zhang, J., Zhang, L., Liu, P., Xie, Y., & Zhou, Q. (2016). Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials. Journal of Chemotherapy (Taylor & Francis Ltd), 28(4), 328–334. https://doi.org/10.1179/1973947815Y.0000000053
Chicago
Wang, Zexing, Jun Zhang, Liang Zhang, Pengying Liu, Yamin Xie, and Qin Zhou. 2016. “Risk of Gastrointestinal Perforation in Cancer Patients Receiving Ramucirumab: A Meta-Analysis of Randomized Controlled Trials.” Journal of Chemotherapy (Taylor & Francis Ltd) 28 (4): 328–34. doi:10.1179/1973947815Y.0000000053.